Spondyloarthritis & psoriatic arthritis
Sex Differences in Medication Discontinuation in Axial Spondyloarthritis
Authors' conclusion
In a large US registry, women with axSpA were more likely to discontinue TNFi and IL-17i than men.
Study context
- Population
- New users of tumor necrosis factor inhibitors (TNFi), IL-17i or JAK inhibitors (JAKi) with axial spondyloarthritis (axSpA), Rheumatology Informatics System for Effectiveness (RISE) Registry (2003–2025), US58.3% female
- Participants
- 7,200 users
- Exposure
- Women vs men initiating TNFi, IL-17i or JAKi
- Outcome
- Medication discontinuation by sex
Methodological detailsregistry-based, new-user design, Cox regression adjusted for sociodemographic and clinical factors
- Registry-based
- New-user design
- Cox regression adjusted for sociodemographic and clinical factors
Main finding
As reported in the abstract
Discontinuation, by drug class
Women vs MenHazard ratio (95% CI)
TNFi users (N = 6,256)
1.24(1.16–1.32)
IL-17i users (n = 693)
1.25(1.01–1.54)
Observational data: associations, not effects.
Further findings
Treatment continuation by sex and age group, TNFi users
- Women under 65 years had the lowest probability of treatment continuation
Interaction between sex and age, race or area deprivation index (ADI)
- No statistically significant interaction
Original publication
Sex Differences in Medication Discontinuation in Axial Spondyloarthritis. Arthritis Care Res (Hoboken). Published 4 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →